29,696 Shares in REGENXBIO Inc. (NASDAQ:RGNX) Purchased by BIT Capital GmbH

BIT Capital GmbH acquired a new stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 29,696 shares of the biotechnology company’s stock, valued at approximately $230,000. BIT Capital GmbH owned approximately 0.06% of REGENXBIO at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. JPMorgan Chase & Co. grew its position in shares of REGENXBIO by 67.0% in the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company’s stock valued at $31,975,000 after purchasing an additional 1,659,206 shares in the last quarter. Redmile Group LLC grew its holdings in REGENXBIO by 7.1% in the 3rd quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company’s stock valued at $51,327,000 after buying an additional 323,100 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in REGENXBIO by 53.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock valued at $6,621,000 after buying an additional 296,700 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of REGENXBIO in the 4th quarter worth $1,062,000. Finally, Raymond James Financial Inc. purchased a new position in shares of REGENXBIO during the 4th quarter worth $568,000. 88.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Royal Bank of Canada restated an “outperform” rating and set a $30.00 price objective on shares of REGENXBIO in a research report on Tuesday, January 21st. Leerink Partners set a $24.00 price target on shares of REGENXBIO in a research note on Tuesday, March 18th. The Goldman Sachs Group lowered shares of REGENXBIO from a “buy” rating to a “neutral” rating and reduced their price target for the company from $38.00 to $14.00 in a research report on Tuesday, February 11th. HC Wainwright lowered their price objective on REGENXBIO from $36.00 to $34.00 and set a “buy” rating for the company in a research report on Monday, March 17th. Finally, Raymond James started coverage on REGENXBIO in a research report on Friday, February 7th. They issued an “outperform” rating and a $27.00 target price on the stock. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $32.78.

REGENXBIO Price Performance

Shares of REGENXBIO stock opened at $8.20 on Thursday. The stock has a market capitalization of $410.71 million, a price-to-earnings ratio of -1.63 and a beta of 1.35. The business has a 50-day moving average of $7.37 and a 200 day moving average of $8.82. REGENXBIO Inc. has a 12 month low of $5.62 and a 12 month high of $22.42.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.27) by $0.26. The firm had revenue of $21.21 million during the quarter, compared to analysts’ expectations of $23.70 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. Equities research analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.